GTS-21 attenuates loss of body mass, muscle mass, and function in rats having systemic inflammation with and without disuse atrophy
- 102 Downloads
Muscle changes of critical illness are attributed to systemic inflammatory responses and disuse atrophy. GTS-21 (3-(2,4-dimethoxy-benzylidene)anabaseine), also known as DMBX-A) is a synthetic derivative of the natural product anabaseine that acts as an agonist at α7-acetylcholine receptors (α7nAChRs). Hypothesis tested was that modulation of inflammation by agonist GTS-21 (10 mg/kg b.i.d. intraperitoneally) will attenuate body weight (BW) and muscle changes. Systemic sham inflammation was produced in 125 rats by Cornyebacterium parvum (C.p.) or saline injection on days 0/4/8. Seventy-four rats had one immobilized-limb producing disuse atrophy. GTS-21 effects on BW, tibialis muscle mass (TMM), and function were assessed on day 12. Systemically, methemoglobin levels increased 26-fold with C.p. (p < 0.001) and decreased significantly (p < 0.033) with GTS-21. Control BW increased (+ 30 ± 9 g, mean ± SD) at day 12, but decreased with C.p. and superimposed disuse (p = 0.005). GTS-21 attenuated BW loss in C.p. (p = 0.005). Compared to controls, TMM decreased with C.p. (0.43 ± 0.06 g to 0.26 ± 0.03 g) and with superimposed disuse (0.18 ± 0.04 g); GTS-21 ameliorated TMM loss to 0.32 ± 0.04 (no disuse, p = 0.028) and to 0.22 ± 0.03 (with disuse, p = 0.004). Tetanic tensions decreased with C.p. or disuse and GTS-21 attenuated tension decrease in animals with disuse (p = 0.006) and in animals with C.p. and disuse (p = 0.029). C.p.-induced 11-fold increased muscle α7nAChR expression was decreased by > 60% with GTS-21 treatment. In conclusion, GTS-21 modulates systemic inflammation, evidenced by both decreased methemoglobin levels and decrease of α7nAChR expression, and mitigates inflammation-mediated loss of BW, TMM, fiber size, and function.
Keywords3-(2,4-dimethoxybenzylidene)anabaseine Critical care DMXB Muscular disorders Atrophic Muscle weakness
The authors would like to thank Univ. Prof. Dr. med., Dipl.-Phys. Eberhard Kochs for his continued scientific advice and support and the following collaborators for their technical assistance: Sandra Baur, Andreas Blaschke, Nina Bayer, Anna Folz, Eva Nuspl (all from Klinikum rechts der Isar, Technical University of Munich, Germany).
Support in Munich, Germany, was provided solely from institutional and/or departmental sources. Jeevendra Martyn was supported in part by grants from the National Institutes of Health, Bethesda, MD (P50-GM21500, Project I, and RO1-GM 118947) and grants from Shriners Hospitals for Children®—Tampa, FL.
Compliance with ethical standards
Conflict of interest
The authors declare that they have no competing interests.
Research involving animals
All applicable international, national, and/or institutional guidelines for the care and use of animals were followed. All procedures performed in studies involving animals were in accordance with the ethical standards of the institution or practice at which the studies were conducted. This animal study was approved by the institutional review board (Subcommittee on Research Animal Care, Committee on Research, Massachusetts General Hospital, #2010N000168).
- 2.Briggs CA, Anderson DJ, Brioni JD, Buccafusco JJ, Buckley MJ, Campbell JE, Decker MW, Donnelly-Roberts D, Elliott RL, Gopalakrishnan M, Holladay MW, Hui YH, Jackson WJ, Kim DJ, Marsh KC, O'Neill A, Prendergast MA, Ryther KB, Sullivan JP, Arneric SP (1997) Functional characterization of the novel neuronal nicotinic acetylcholine receptor ligand GTS-21 in vitro and in vivo. Pharmacol Biochem Behav 57:231–241CrossRefPubMedCentralGoogle Scholar
- 11.Freedman R, Olincy A, Buchanan RW, Harris JG, Gold JM, Johnson L, Allensworth D, Guzman-Bonilla A, Clement B, Ball MP, Kutnick J, Pender V, Martin LF, Stevens KE, Wagner BD, Zerbe GO, Soti F, Kem WR (2008) Initial phase 2 trial of a nicotinic agonist in schizophrenia. Am J Psychiatry 165:1040–1047CrossRefPubMedCentralGoogle Scholar
- 20.Herridge MS, Cheung AM, Tansey CM, Matte-Martyn A, Diaz-Granados N, Al-Saidi F, Cooper AB, Guest CB, Mazer CD, Mehta S, Stewart TE, Barr A, Cook D, Slutsky AS, Canadian critical care trials G (2003) One-year outcomes in survivors of the acute respiratory distress syndrome. N Engl J Med 348:683–693CrossRefPubMedCentralGoogle Scholar
- 21.Herridge MS, Tansey CM, Matte A, Tomlinson G, Diaz-Granados N, Cooper A, Guest CB, Mazer CD, Mehta S, Stewart TE, Kudlow P, Cook D, Slutsky AS, Cheung AM, Canadian critical care trials G (2011) Functional disability 5 years after acute respiratory distress syndrome. N Engl J Med 364:1293–1304CrossRefPubMedCentralGoogle Scholar
- 29.Kem WR, Olincy A, Johnson L, Harris J, Wagner BD, Buchanan RW, Christians U, Freedman R (2017) Pharmacokinetic limitations on effects of an alpha7-nicotinic receptor agonist in schizophrenia: randomized trial with an extended-release formulation. NeuropsychopharmacologyGoogle Scholar
- 31.Khan MA, Khan MF, Kashiwagi S, Kem WR, Yasuhara S, Kaneki M, Tompkins RG, Martyn JA (2017) An alpha7 nicotinic acetylcholine receptor agonist (GTS-21) promotes C2C12 Myonuclear accretion in association with release of Interleukin-6 (IL-6) and improves survival in burned mice. Shock 48:227–235CrossRefPubMedCentralGoogle Scholar
- 35.Kox M, Pompe JC, Peters E, Vaneker M, van der Laak JW, van der Hoeven JG, Scheffer GJ, Hoedemaekers CW, Pickkers P (2011) alpha7 nicotinic acetylcholine receptor agonist GTS-21 attenuates ventilator-induced tumour necrosis factor-alpha production and lung injury. Br J Anaesth 107:559–566CrossRefPubMedCentralGoogle Scholar
- 38.Langhans C, Weber-Carstens S, Schmidt F, Hamati J, Kny M, Zhu X, Wollersheim T, Koch S, Krebs M, Schulz H, Lodka D, Saar K, Labeit S, Spies C, Hubner N, Spranger J, Spuler S, Boschmann M, Dittmar G, Butler-Browne G, Mouly V, Fielitz J (2014) Inflammation-induced acute phase response in skeletal muscle and critical illness myopathy. PLoS One 9:e92048CrossRefPubMedCentralGoogle Scholar
- 43.Liu L, Min S, Li W, Wei K, Luo J, Wu G, Ao L, Cao J, Wang B, Wang Z (2014) Pharmacodynamic changes with vecuronium in sepsis are associated with expression of alpha7- and gamma-nicotinic acetylcholine receptor in an experimental rat model of neuromyopathy. Br J Anaesth 112:159–168CrossRefPubMedCentralGoogle Scholar
- 44.Maldifassi MC, Atienza G, Arnalich F, Lopez-Collazo E, Cedillo JL, Martin-Sanchez C, Bordas A, Renart J, Montiel C (2014) A new IRAK-M-mediated mechanism implicated in the anti-inflammatory effect of nicotine via alpha7 nicotinic receptors in human macrophages. PLoS One 9:e108397CrossRefPubMedCentralGoogle Scholar
- 50.Olincy A, Harris JG, Johnson LL, Pender V, Kongs S, Allensworth D, Ellis J, Zerbe GO, Leonard S, Stevens KE, Stevens JO, Martin L, Adler LE, Soti F, Kem WR, Freedman R (2006) Proof-of-concept trial of an alpha7 nicotinic agonist in schizophrenia. Arch Gen Psychiatry 63:630–638CrossRefPubMedCentralGoogle Scholar
- 53.Puthucheary ZA, Rawal J, McPhail M, Connolly B, Ratnayake G, Chan P, Hopkinson NS, Padhke R, Dew T, Sidhu PS, Velloso C, Seymour J, Agley CC, Selby A, Limb M, Edwards LM, Smith K, Rowlerson A, Rennie MJ, Moxham J, Harridge SDR, Hart N, Montgomery HE (2013) Acute skeletal muscle wasting in critical illness. JAMA - J Am Med Assoc 310:1591–1600CrossRefGoogle Scholar
- 55.Schaller SJ, Anstey M, Blobner M, Edrich T, Grabitz SD, Gradwohl-Matis I, Heim M, Houle T, Kurth T, Latronico N, Lee J, Meyer MJ, Peponis T, Talmor D, Velmahos GC, Waak K, Walz JM, Zafonte R, Eikermann M, International early S-gMRI (2016) Early, goal-directed mobilisation in the surgical intensive care unit: a randomised controlled trial. Lancet 388:1377–1388CrossRefPubMedCentralGoogle Scholar
- 56.Schweickert WD, Pohlman MC, Pohlman AS, Nigos C, Pawlik AJ, Esbrook CL, Spears L, Miller M, Franczyk M, Deprizio D, Schmidt GA, Bowman A, Barr R, McCallister KE, Hall JB, Kress JP (2009) Early physical and occupational therapy in mechanically ventilated, critically ill patients: a randomised controlled trial. Lancet 373:1874–1882CrossRefPubMedCentralGoogle Scholar
- 62.van Maanen MA, Papke RL, Koopman FA, Koepke J, Bevaart L, Clark R, Lamppu D, Elbaum D, LaRosa GJ, Tak PP, Vervoordeldonk MJ (2015) Two novel alpha7 nicotinic acetylcholine receptor ligands: in vitro properties and their efficacy in collagen-induced arthritis in mice. PLoS One 10:e0116227CrossRefPubMedCentralGoogle Scholar
- 63.Veihelmann A, Brill T, Blobner M, Scheller I, Mayer B, Prolls M, Himpel S, Stadler J (1997) Inhibition of nitric oxide synthesis improves detoxication in inflammatory liver dysfunction in vivo. Am J Phys 273:G530–G536Google Scholar
- 65.Weber-Carstens S, Schneider J, Wollersheim T, Assmann A, Bierbrauer J, Marg A, Al Hasani H, Chadt A, Wenzel K, Koch S, Fielitz J, Kleber C, Faust K, Mai K, Spies CD, Luft FC, Boschmann M, Spranger J, Spuler S (2013) Critical illness myopathy and GLUT4: significance of insulin and muscle contraction. Am J Respir Crit Care Med 187:387–396CrossRefPubMedCentralGoogle Scholar
- 66.Wollersheim T, Woehlecke J, Krebs M, Hamati J, Lodka D, Luther-Schroeder A, Langhans C, Haas K, Radtke T, Kleber C, Spies C, Labeit S, Schuelke M, Spuler S, Spranger J, Weber-Carstens S, Fielitz J (2014) Dynamics of myosin degradation in intensive care unit-acquired weakness during severe critical illness. Intensive Care Med 40:528–538CrossRefPubMedCentralGoogle Scholar